Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.

Abstract: Provided is a conjugate for photodynamic diagnosis or treatment in which a peptide binds with a photosensitizer via an intracellularly degradable linkage, and a composition for photodynamic diagnosis or treatment including the same. The conjugate generates no fluorescent signal and reactive oxygen in normal tissues or during the circulation in the blood by quenching a fluorescent signal and reactive oxygen generation ability of the photosensitizer. After the conjugate is selectively absorbed into target cells, a linker is degraded in cells to increase the distance between tryptophan included in the peptide and the photosensitizer, and the quenching action is terminated to generate a strong fluorescence signal and induce active generation of reactive oxygen. The conjugate has high tissue permeability, shows a high photodynamic therapeutic effect in only target cells while being safe in normal cells, and can obtain a good diagnostic image having a high ratio of target signal to background.

Abstract: The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.

Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.

Abstract: An information processing apparatus (2000) detects an abnormal region (30) from a moving image frame (14). The abnormal region (30) is a region that is estimated to represent an abnormal part inside a body of a subject. The information processing apparatus (2000) generates and outputs output information based on the number of detected abnormal regions (30).

Abstract: A processor receives an input of finding information indicating at least one finding, which is desired to be searched for, on a query base image, which includes a part desired to be searched for and is a source of a query image, to derive the query image to which the finding has been added, derives at least one added finding feature amount indicating an image feature for the added finding, and derives a query normal feature amount indicating an image feature for a normal region included in the part in the query base image. The processor derives similarities between the query image and a plurality of reference images including findings on the basis of comparisons between the added finding feature amount and the query normal feature amount and the like with reference to an image database in which the plurality of reference images have been registered and extracts the reference image that is similar to the query image as a similar image from the image database on the basis of the similarities.

Abstract: Disclosed is a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, including a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, including measuring the miRNA(s) in vitro.

Abstract: Provided are CAR-T compositions that are directed to HLA-DR. Certain provided HLA-DR CAR compositions exhibit low affinity for a polymorphic region of HLA-DR of a subject. Various in vitro and in vivo methods and reagents related to HLA-DR CAR-T are also provided. Methods described herein can include, for example, characterization of HLA-DR binding, proliferation of T-cells, as well as prevention and/or therapeutic treatment of cancer using a HLA-DR CAR-T composition provided herein.

Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.

Abstract: The present invention relates to a method for predicting the reactivity of a cancer-targeted therapeutic agent, in which various types of target proteins targeted by a cancer-targeted therapeutic agent are simultaneously quantified through triple quadrupole mass spectrometry. The inventors of the present invention carefully selected peptide sequences with high selectivity in nanoflow liquid chromatography-triple quadrupole mass spectrometry, in response to clinical needs, and optimized peptide combinations and experimental conditions to enable multiple peptide quantification.

Abstract: A full-thickness resection method for a gastrointestinal tract includes forming a pair of first markings in surrounding tissue on both sides of a lesion to sandwich the lesion therebetween; performing a full-thickness resection to a portion including the lesion; identifying a pair of suture locations in the vicinity of the pair of first markings; and suturing the pair of first suture locations.

Abstract: An embodiment according to the present invention provides a kit or device for detection of bladder cancer, and a method for detecting bladder cancer. An embodiment according to the present invention relates to: a kit or device for detection of bladder cancer, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting bladder cancer, including measuring the miRNA(s) in vitro.

Abstract: The present disclosure relates to a composition for preventing or treating lung cancer, comprising a compound isolated from a Cephalotaxus extract as an active ingredient. Isoharringtonine, which is the compound isolated from the Cephalotaxus extract according to the present disclosure, induces apoptosis and exhibits the effect of inhibiting the growth of non-small cell lung cancer cell lines, and thus can be useful in the prevention or treatment of lung cancer. In addition, the combined treatment of isoharringtonine and siNR4A1 enhances anticancer activity, and the combined treatment of isoharringtonine and cisplatin, which is a conventional anticancer drug, induces a high anticancer effect at a low concentration of cisplatin, thereby reducing side effects of anticancer treatment.

Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.

Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.

Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.

Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

Abstract: Disclosed is a sequence analysis method for analyzing nucleic acid sequence, the sequence analysis method including: obtaining a plurality of read sequences read from the nucleic acid sequence; and determining each nucleic acid sequence by aligning each read sequence with reference to a single reference sequence, wherein the reference sequence includes at least a first rearrangement sequence and a second rearrangement sequence that is different from the first rearrangement sequence.

Abstract: Provided is a method of assisting breast cancer diagnosis, comprising: a measuring step for measuring an amount of laminin 5 or laminin ?3 in a specimen; and an information-providing step for providing information for breast cancer diagnosis based on the amount of laminin 5 or laminin ?3 thus measured. Provided is a test kit for breast cancer comprising an anti-laminin 5 antibody or an anti-laminin ?3 antibody.

Abstract: Disclosed is an apparatus for measuring the distribution of radiation dose emitted from a brachytherapy insertion tool, the apparatus including a housing having defined therein a measurement space in which the brachytherapy insertion tool is located, a fluorescent member disposed at the housing, the fluorescent member being configured to react with radiation emitted to the measurement space and to emit light, a camera disposed in the housing, and a cover coupled to one surface of the housing, the cover being configured to cover the fluorescent member. The portion of the fluorescent member to which radiation from a radiation source of the brachytherapy insertion tool is applied reacts with the radiation and generates light, brightness of the light varies depending on distribution of the radiation, and the position at which the light is bright is calculated to measure the direction in which the brachytherapy insertion tool has no shielding.